| Primary |
| Gastritis |
14.5% |
| Hypertension |
11.7% |
| Prophylaxis |
7.2% |
| Gastric Ulcer |
6.7% |
| Gastrooesophageal Reflux Disease |
6.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
5.7% |
| Asthma |
4.7% |
| Pneumonia |
4.3% |
| Anorexia |
3.9% |
| Shock |
3.8% |
| Constipation |
3.7% |
| Sedation |
3.7% |
| Diarrhoea |
3.6% |
| Nasopharyngitis |
3.0% |
| Abdominal Pain Upper |
2.9% |
| Cerebral Infarction |
2.9% |
| Gastric Ulcer Haemorrhage |
2.9% |
| Myocardial Infarction |
2.9% |
| Insomnia |
2.8% |
| Pyrexia |
2.8% |
|
| Rhabdomyolysis |
21.3% |
| Liver Disorder |
14.7% |
| White Blood Cell Count Decreased |
5.7% |
| Drug Ineffective |
5.2% |
| Renal Impairment |
5.2% |
| Toxic Epidermal Necrolysis |
5.2% |
| Vomiting |
4.3% |
| Parkinsonism |
4.0% |
| Tubulointerstitial Nephritis |
4.0% |
| Drug Eruption |
3.7% |
| Renal Failure Acute |
3.7% |
| Shock |
3.4% |
| Pancytopenia |
2.9% |
| Thrombocytopenia |
2.9% |
| Stevens-johnson Syndrome |
2.6% |
| Anaphylactic Shock |
2.3% |
| Electrocardiogram Qt Prolonged |
2.3% |
| Platelet Count Decreased |
2.3% |
| Torsade De Pointes |
2.3% |
| Blood Creatine Phosphokinase Increased |
2.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
35.1% |
| Product Used For Unknown Indication |
8.4% |
| Hypertension |
7.1% |
| Agitation |
5.7% |
| Sedation |
4.9% |
| Opportunistic Infection Prophylaxis |
3.7% |
| Gastrooesophageal Reflux Disease |
3.6% |
| Depression |
2.9% |
| Gastritis |
2.9% |
| Gastric Ulcer |
2.8% |
| Antibiotic Level |
2.7% |
| Pancreatitis Acute |
2.7% |
| Shock |
2.7% |
| Asthma |
2.4% |
| Polyuria |
2.4% |
| Myocardial Infarction |
2.0% |
| Pain |
2.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.0% |
| Anaesthesia |
2.0% |
| Dyspepsia |
1.9% |
|
| Liver Disorder |
11.0% |
| Toxic Epidermal Necrolysis |
9.8% |
| Ventricular Extrasystoles |
9.8% |
| Rhabdomyolysis |
9.1% |
| Renal Impairment |
7.3% |
| Vomiting |
7.3% |
| Urticaria |
5.5% |
| Pancreatitis |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Postoperative Infection |
3.7% |
| Chest Pain |
3.0% |
| Erythema Multiforme |
3.0% |
| Hyponatraemia |
3.0% |
| Intra-uterine Death |
3.0% |
| Myalgia |
3.0% |
| Nausea |
3.0% |
| Drug Eruption |
2.4% |
| Malaise |
2.4% |
| Myocardial Infarction |
2.4% |
| Sepsis |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.3% |
| Drug Use For Unknown Indication |
22.1% |
| Pain |
5.0% |
| Gastrooesophageal Reflux Disease |
4.8% |
| Hypertension |
4.7% |
| Premedication |
2.9% |
| Depression |
2.8% |
| Anxiety |
2.2% |
| Prophylaxis |
2.1% |
| Nausea |
2.1% |
| Multiple Myeloma |
2.1% |
| Osteoporosis |
1.9% |
| Diabetes Mellitus |
1.8% |
| Breast Cancer |
1.7% |
| Rheumatoid Arthritis |
1.6% |
| Dyspepsia |
1.5% |
| Contraception |
1.4% |
| Hiv Infection |
1.4% |
| Insomnia |
1.3% |
| Asthma |
1.3% |
|
| Vomiting |
16.7% |
| Weight Decreased |
13.6% |
| Weight Increased |
6.6% |
| Pain |
5.9% |
| Nausea |
5.2% |
| Urinary Tract Infection |
4.9% |
| Sepsis |
4.9% |
| Death |
4.7% |
| Pulmonary Embolism |
4.2% |
| Pneumonia |
3.8% |
| Thrombocytopenia |
3.8% |
| Drug Ineffective |
3.5% |
| Pyrexia |
3.1% |
| Rash |
3.0% |
| Dyspnoea |
2.8% |
| Urticaria |
2.8% |
| Tremor |
2.8% |
| Myocardial Infarction |
2.6% |
| Type 2 Diabetes Mellitus |
2.5% |
| White Blood Cell Count Decreased |
2.5% |
|
| Interacting |
| Chronic Myeloid Leukaemia |
26.3% |
| Gastrooesophageal Reflux Disease |
15.8% |
| Chromosome Analysis Abnormal |
10.5% |
| Neuropathy Peripheral |
10.5% |
| Abdominal Pain Upper |
5.3% |
| Back Pain |
5.3% |
| Blood Cholesterol Increased |
5.3% |
| Coagulopathy |
5.3% |
| Coronary Artery Bypass |
5.3% |
| Non-hodgkin's Lymphoma |
5.3% |
| Stent Placement |
5.3% |
|
| Drug Interaction |
25.0% |
| Chills |
12.5% |
| Coronary Arterial Stent Insertion |
12.5% |
| Fall |
12.5% |
| Myalgia |
12.5% |
| Nausea |
12.5% |
| Vomiting |
12.5% |
|
